Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06832059

Precision Nutrition Versus Standard Dietary Care: Continuous Glucose Monitoring as a Tool for Guided Nutrition Care in Type 2 Diabetes - The PRECISE-DIET Trial. -A Pilot Study

The primary aim of this pilot study is to assess the feasibility of a 12-week dietary intervention combined with the use of CGM in adults with T2D. The results of the pilot study will provide insights into recruitment, design, and the effectiveness of the intervention for the future long-term (12-month) PRECISE-DIET STUDY

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Steno Diabetes Center Copenhagen

Herlev, 2730, Denmark

About this study

In recent decades, there has been a significant rise in the development and use of glucose lowering drugs aimed at improving glycemic control in individuals with type 2 diabetes (T2D). Despite medical advancements, more than one-third of the danish population with T2D have a hemoglobin A1c (HbA1c) exceeding the recommended thresholds. One limiting factor in supporting individuals achieve their glycaemic target may be driven by substantial postprandial increases in plasma glucose levels, which is influenced by the quantity and type of carbohydrates in meals, underscoring the critical role of dietary interventions as an integral component of T2D management.

Recent studies have demonstrated that the use of continuous glucose monitors (CGMs), which allow individuals to track their glucose profiles continuously throughout the day, improves glycemic control in T2D patients. However, these studies often exclude dietary interventions, which could potentially yield greater improvements in blood glucose regulation.

Nutritional research in recent years has focused on dietary patterns such as low-fat diets, the paleo diet, and vegan diets. Nevertheless, these studies have not sufficiently addressed individualized dietary adjustments to mitigate postprandial glucose excursions, despite their substantial importance for glycemic control.

Several clinical studies have revealed significant inter-individual variations in glycemic responses to identical standardized meals, highlighting the necessity of a personalized approach to dietary recommendations, particularly with a focus on carbohydrate intake.

The primary aim of this pilot study is to assess the feasibility of a 12-week dietary intervention combined with the use of CGM in adults with T2D. The results of the pilot study will provide insights into recruitment, design, and the effectiveness of the intervention for the future long-term (12-month) PRECISE-DIET STUDY

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • T2D
  • Diabetes duration of ≥12 months
  • ≥18 years of age
  • HbA1c ≥58 mmol/mol
  • Attending the SDCC outpatient clinic
  • Provided voluntary signed informed consent.

Exclusion criteria

  • Inability to understand the patient information.
  • Complications which do not permit to lowering HbA1c to <58 mmol/mol.
  • Treatment with insulin.
  • Low daily carbohydrate intake (defined as below 25 E% or 100 g/day) prior to study inclusion.
  • Systematic use of corticosteroids.
  • Using or requiring a specialized diet (e.g., kidney diet).
  • Circumstances that affect HbA1c (e.g., liver disease and anaemia).
  • Known or suspected drug or alcohol abuse (judged by the investigator).
  • Pregnancy or breastfeeding or plans of pregnancy within the study period.
  • Participation in other clinical trials.

Treatment and study plan

The precise diet intervention

Other

The intervention includes training and education in CGM use and reduction in overall carbohydrate intake guided by individualized flexible nutrition recommendations, with adjustments made according to postprandial blood glucose responses. Staff will guide participants in the daily carbohydrate intake with personalized adjustments to accommodate individual needs by the individuals. The primary goal is to minimize the participant's time spent above 10 mmol/l

Primary outcomes

  1. Fidelity testing

    Time frame: 12 weeks after baseline

    Participants will be invited to a workshop to evaluate the intervention and its components. Procedures from fidelity testing will be applied in the evaluation. These specific topics will be evaluated:

    • Study design

    o Is the design appropriate? E.g., number of visits, CGM use, dietetic feedback?

    • Sampling strategy

    o E.g., how many participated, recruitment methods, sample diversity?

    • Treatment receipt
    • "What is learned?"
    • Is the intervention relevant to and accepted by the participants?
    • Treatment enactment
    • What is actually used and done?
    • Do participants' "behavioural skills" improve?

Secondary outcomes

  1. HbA1c (mmol/mol)

    Time frame: Measured at baseline and after 12 weeks

    Assessed from blood samples

  2. Time in range (TIR)

    Time frame: Measured at baseline and after 12 weeks

    Time spent in time in range 3.9 mmol/l - 10.0 mmol/l from CGM data

  3. Time above range (TAR)

    Time frame: Measured at baseline and after 12 weeks

    Time spent in time above range 10.1-13.9 mmol/l from CGM data

  4. Time below range (TBR)

    Time frame: Measured at baseline and after 12 weeks

    Time spent in time below range <3.9 mmol/l from from CGM data

  5. Coefficient of variation (CV)

    Time frame: Measured at baseline and after 12 weeks

    Percentage coefficient of variation in glucose differences

  6. Estimated HbA1c

    Time frame: Measured at baseline and after 12 weeks

    Estimated HbA1c (14-days average of the CGM data)

  7. Body mass index (kg/m^2)

    Time frame: Measured at baseline and after 12 weeks

    Calculated from body weight (kg) and height (m).

  8. Body weight (kg)

    Time frame: Measured at baseline and after 12 weeks

    Measured on a digital scale

  9. Waist circumference (cm)

    Time frame: Measured at baseline and after 12 weeks

    Measured using tape measure.

  10. Hip circumference (cm)

    Time frame: Measured at baseline and after 12 weeks

    Measured using tape measure

  11. Systolic blood pressure (mmHg)

    Time frame: Measured at baseline and after 12 weeks

    Measured under resting

  12. Diastolic blood pressure (mmHg)

    Time frame: Measured at baseline and after 12 weeks

    Measured under resting

  13. Self-reported diabetes distress

    Time frame: Measured at baseline and after 12 weeks

    Assessed from the Problem Areas in Diabetes Scale comprising of twenty emotional-distress questions. Each item can be rated from 0 to 5.

  14. Self-reported treatment satisfaction

    Time frame: Measured at baseline and after 12 weeks

    Assessed from the questionnaire Diabetes Treatment Satisfaction Questionnaire (DTSQ).

  15. Dietary intake

    Time frame: Measured at baseline and after 12 weeks

    Dietary intake (total energy intake and macronutrient composition based on 3-days' diet records)

Other outcomes

  1. Changes in glucose lowering drugs

    Time frame: Measured at baseline and after 12 weeks

    Medication status, change in doses or discontinuation of medicine

  2. Personality trait assesment

    Time frame: Baseline

    Assesed fromt the BIG FIVE Inventory questionnaire (BFI-44). Comprising of 44 items.

  3. Physical activity

    Time frame: Measured at baseline and after 12 weeks

    Physical activity levels measured by X3 accelerometers

Sponsors and collaborators

Lead sponsor

Steno Diabetes Center Copenhagen

Other

Registry information

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Feb 18, 2025
Registry last updated
Jul 1, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.